Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on their clinic effectiveness. These drugs appear to exert their psychedelic effects through their agonist or partial agonist activity at the serotonergic 5-HT 2A receptor, though they also have affinity for other metabotropic serotonin receptors. Hallucinogen binding affects a wide range of intracellular signalling pathways, the precise nature of which remains incompletely understood. They alter the serotonergic tone of brainstem raphe nuclei that project through the brain; they interact with receptors in the prefrontal cortex altering connectivity patterns and intracellular functioning; and they disrupt inhibitory control of sensory input via the thalamus to the cortex. The serotonergic system has long been implicated in anxiety and depressive disorders, and is a major target of most existing antidepressants. Classical hallucinogens alter the functioning of this system, but not in the same way current medications do: whilst there are identified receptors and neurotransmitter pathways through which hallucinogens could therein produce therapeutic effects, the neurobiology of this remains speculative at this time. There is currently an extremely limited but growing literature on hallucinogen safety and clinical application. The drugs appear well tolerated by healthy controls and clinical populations, and the rapid tolerance to repeated administration might reduce the possibility of dependency. Clinical trials reported over the past decade have generally shown positive therapeutic potential, but they are notably few in number. Legislative policy has had a freezing effect on evaluation of these compounds, a better understanding of which might improve our knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“Indeed, there is robust evidence for increased levels of cytokines such as tumour necrosis factorα (TNF-α) and IL-6 in major depression [Dowlati et al. 2010] and it has been shown that in patients receiving amitriptyline, a tricyclic antidepressant, treatment response is associated with a significant decrease in TNF-α…”
BackgroundRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“2013] and that behavioural effects of antidepressants can be blocked by directly disrupting neurogenesis [Santarelli et al. 2003].”
BackgroundThe effect of mindfulness based therapy on anxiety and depression: A meta analytic review
Hofmann, S. G., Sawyer, A. T., Witt, A. A., & Oh, D. (2010) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0018555 · Cited by 3,846
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“2012] and there is evidence that depression is partially linked to insufficient neurogenesis and neurotrophic activity [Krishnan and Nestler, 2008].”
BackgroundGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Default Mode Network Activity and Connectivity in Psychopathology
Whitfield-Gabrieli, S., & Ford, J. M. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143049 · Cited by 1,465 · cited 2×
“…of the DMN and broader dysconnectivity between this and the extrinsic networks has been robustly associated with mental illness, most notably so the self-referential processes in depression that may be difficult to disengage, such as rumination [Whitfield-Gabrieli and Ford, 2012; Caddy et al.”
BackgroundBrewer, J. A., Worhunsky, P. D., Gray, J. R., Tang, Y.-Y., Weber, J., & Kober, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112029108 · Cited by 1,409
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“Grob and colleagues investigated administration of psilocybin to advanced-stage, mood-disordered cancer patients on measures of depression, state– trait anxiety and mood states [Grob et al. 2011].”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.34 · Cited by 1,068
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Fjorback, L. O., Arendt, M., Ørnbøl, E., Fink, P., & Walach, H. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01704.x · Cited by 803
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 5×
“Moreover, suppressive changes to mPFC activity are associated with a list of effective treatments for depression, including SSRIs [Kennedy et al.”
BackgroundInfluentialGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 11×
“Based on this finding, Vollenweider and Kometer have suggested that the indirect activation of glutamate networks by classical hallucinogens enhances neuroplasticity, specifically so via the AMPA (α-amino-3-hydroxyl-5-methyl4-isoxazole-propionic acid) receptor, with subsequent downstream increases in the cellular prot…”
BackgroundInfluentialKennedy, S. H., Evans, K. R., Krüger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.899 · Cited by 710
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388 · cited 1×
“2008], which mediates cytokine-induced inhibition of neurogenesis in human hippocampal progenitor cell lines [Zunszain et al. 2012].”
BackgroundPsychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Celada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Serotonin activates the hypothalamic–Pituitary–Adrenal axis via serotonin 2C receptor stimulation
Heisler, L. K., Pronchuk, N., Nonogaki, K., Zhou, L., Raber, J., Tung, L., Yeo, G. S. H., O'Rahilly, S., Colmers, W. F., Elmquist, J. K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2584-06.2007 · Cited by 292
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“Interestingly, Catlow and colleagues have investigated the effects of psilocybin, 25I-NBOMe (a synthetic phenethylamine) and ketanserin administrations on hippocampal neurogenesis and extinction of fear conditioning in adult rats [Catlow et al. 2013].”
BackgroundFunctional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256 · cited 1×
“Further analysis of the sample revealed increased functional connectivity of the so-called default-mode network (DMN), comprised of the posterior cingulate cortex, mPFC and lateral inferior parietal cortex, and the task-positive network (TPN), comprised prefrontal and parietal structures [Carhart-Harris et al. 2013].”
BackgroundBéïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · cited 1×
“Modulation of glutamatergic functioning: altering BDNF and neurogenesis Several studies have presented evidence that there is an increase of glutamate-dependent activity in prefrontal areas, induced by agonism of 5-HT2A receptors by classical hallucinogens [Aghajanian and Marek, 1997, 1999; Beique et al. 2007].”
BackgroundGouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 2×
“Further, long-term changes to intracellular signalling pathways may occur due to drug-induced alterations in gene expression, with evidence suggesting DOI may increase expression of several genes including c-fos, arc, sgk, ania3 and egr2 [Leslie et al. 1993; Pei et al. 2000; Nichols and Sanders-Bush, 2002].”
BackgroundBDNF control of adult SVZ neurogenesis
Bath, K. G., Akins, M. R., & Lee, F. S. (2012) · Developmental Psychobiology · doi:10.1002/dev.20546 · Cited by 146 · cited 1×
“BDNF may play a vital role in adult neurogenesis [Bath et al. 2012] and there is evidence that depression is partially linked to insufficient neurogenesis and neurotrophic activity [Krishnan and Nestler, 2008].”
BackgroundLithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140 · cited 1×
“Activation of the 5-HT2A receptor subtype stimulates phospholipase C (PLC), which leads to downstream activation of protein kinase C (PKC) as well as increased release of Ca2+ from intracellular stores [Brown and Tracy, 2013].”
BackgroundSelf-citationAn investigation of brain processes supporting meditation
Bærentsen, K. B., Stødkilde-Jørgensen, H., Sommerlund, B., Hartmann, T., Damsgaard-Madsen, J., Fosnæs, M., & Green, A. C. (2010) · Cognitive Processing · doi:10.1007/s10339-009-0342-3 · Cited by 128
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…is a viable antidepressant target, are the growing number of studies demonstrating the antidepressant potential of 5-HT2AR agonist psychedelics (Baumeister et al., 2014; Buchborn et al., 2014; Carhart-Harris et al., 2016b; Griffiths et al., 2016; Grob et al., 2011; Osorio Fde et al., 2015;…”
BackgroundReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
Self-citation
Metadata
- Authors
- Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-03-17
- Volume
- 4
- Issue
- 4
- Pages
- 156-169
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2104320372
- Cited by
- 121
- References
- 39
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.